These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 38498697)

  • 1. IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs.
    Garcia Jimenez D; Rossi Sebastiano M; Vallaro M; Ermondi G; Caron G
    J Med Chem; 2024 Jul; 67(13):11421-11434. PubMed ID: 38943610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput SFC-MS/MS Method to Measure EPSA and Predict Human Permeability.
    Wang YT; Price E; Feng M; Hulen J; Doktor S; Stresser DM; Maes EM; Ji QC; Jenkins GJ
    J Med Chem; 2024 Jul; ():. PubMed ID: 38976596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs.
    Garcia Jimenez D; Vallaro M; Rossi Sebastiano M; Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    J Med Chem; 2023 Aug; 66(15):10681-10693. PubMed ID: 37490408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space.
    Ermondi G; Vallaro M; Goetz G; Shalaeva M; Caron G
    Eur J Pharm Sci; 2020 Apr; 146():105274. PubMed ID: 32088315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5.
    Rossi Sebastiano M; Garcia Jimenez D; Vallaro M; Caron G; Ermondi G
    J Med Chem; 2022 Sep; 65(18):12068-12083. PubMed ID: 36094896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape.
    Price E; Weinheimer M; Rivkin A; Jenkins G; Nijsen M; Cox PB; DeGoey D
    J Med Chem; 2024 Apr; 67(7):5683-5698. PubMed ID: 38498697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.
    Edmondson SD; Yang B; Fallan C
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1555-1564. PubMed ID: 31047748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances and development strategies of orally bioavailable PROTACs.
    Zeng S; Ye Y; Xia H; Min J; Xu J; Wang Z; Pan Y; Zhou X; Huang W
    Eur J Med Chem; 2023 Dec; 261():115793. PubMed ID: 37708797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the chemical space of orally bioavailable PROTACs.
    Apprato G; Poongavanam V; Garcia Jimenez D; Atilaw Y; Erdelyi M; Ermondi G; Caron G; Kihlberg J
    Drug Discov Today; 2024 Apr; 29(4):103917. PubMed ID: 38360147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-PROTACs: state of the art and perspectives.
    Zhong J; Zhao R; Wang Y; Su YX; Lan X
    Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.